Holen Sie sich die Stockscreener-App
0.6958
9.84%
0.0658
Briacell Therapeutics Corp Aktie (BCTX) Neueste Nachrichten
BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - The Globe and Mail
BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire
My Honest Opinion of Energy Transfer Stock - The Globe and Mail
Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News
How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News
(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com
What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News
What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News
BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News
What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News
What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News
Published on: 2025-08-03 12:02:14 - Jammu Links News
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stockAchieve consistent double-digit returns - Jammu Links News
Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Tremendous return rates - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Invest smarter with comprehensive market analysis - Jammu Links News
How does BriaCell Therapeutics Corp. generate profit in a changing economyProven strategies for superior portfolio growth - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Sky-high return potential - Jammu Links News
Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockDouble-digit growth - Jammu Links News
Off-market insider buying at Atico Mining (ATY) - The Globe and Mail
BriaCell Therapeutics Corp. Recovery Hinges on Volume BreakoutWeekly Setup With 3x Return Potential Published - metal.it
Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - Jammu Links News
BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire
UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com Nigeria
UCLA Health joins BriaCell’s phase 3 breast cancer study - Investing.com
FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan
Foraco International reports Q2 2025 - The Globe and Mail
WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail
BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa
BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire
Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it
BriaCell Secures New Zealand Patent for Cancer Immunotherapy - TipRanks
BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment - Stock Titan
Published on: 2025-07-30 10:30:41 - metal.it
BriaCell Therapeutics Files Patent for Cancer Treatment Platform - AInvest
Is BriaCell Therapeutics Corp. Equity Warrant a Top Dividend Stock to Watch in 2025 - metal.it
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents - GlobeNewswire
BriaCell Therapeutics Corp. Recovery Linked to Earnings SurpriseDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-29 17:12:14 - metal.it
BriaCell Therapeutics Corp. Equity Warrant Recovers — But Is It SustainableReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform - TipRanks
Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan
0.57%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):